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Gastrointestinal (GI) dysfunction has been reported in a substantial number of children with autism spectrum disorders (ASD).
Activation of the mucosal immune response and the presence of abnormal gut microbiota are repeatedly observed in these
children. In children with ASD, the presence of GI dysfunction is often associated with increased irritability, tantrums, aggressive
behaviour, and sleep disturbances. Moreover, modulating gut bacteria with short-term antibiotic treatment can lead to temporary
improvement in behavioral symptoms in some individuals with ASD. Probiotics can influence microbiota composition and
intestinal barrier function and alter mucosal immune responses. The administration of probiotic bacteria to address changes in the
microbiota might, therefore, be a useful novel therapeutic tool with which to restore normal gut microbiota, reduce inflammation,
restore epithelial barrier function, and potentially ameliorate behavioural symptoms associated with some children with ASD. In
this review of the literature, support emerges for the clinical testing of probiotics in ASD, especially in the context of addressing GI
symptoms.
1. Introduction
Autism spectrum disorders (ASD) are serious developmental
disorders with soaring prevalence, affecting 1 in 91 children
in the United States [1]. ASD are characterised by a spectrum
of symptoms, including decreased verbal skills and social
withdrawal, repetitive behavior, insistence to routines, and
unusual response to sensory stimuli. Available treatments
currently include specialized behavioral interventions [2]
and pharmacologic interventions to assist in comorbid or
associated symptoms [3]. With the underlying causes of ASD
still largely undefined, the etiology of ASD is currently the
focus of intensive study, with particular areas of interest
including the role of environmental, genetic, and epigenetic
factors [4, 5]. These efforts share a common goal of devel-
oping new insights which can be translated into novel, ef-
fective strategies for the prevention and treatment of ASD.
The diagnosis of ASD is reached by observation of behav-
ior and the application of well-characterized instruments,
such as the Autism Diagnostic Interview-Revised (ADI-R),
and the Autism Diagnostic Observation Schedule-Generic
(ADOS-G). There is great heterogeneity in the individuals
that receive the ASD diagnosis. This heterogeneity is not
necessarily due to the diagnostic instruments but because the
behaviors displayed by a group of individuals with ASD likely
arise from a variety of causes. However, the causes of ASD are
largely unknown, except in the rare instances in which identi-
fiable genetic abnormalities give rise to a syndrome with ASD
features. Experimental approaches seeking to obtain new
insights into the etiology of ASD are increasingly focused on
the selection of subgroups of ASD individuals who share a
defining group of characteristics. By taking this approach,
it is possible that specific factors associated with certain
aspects of ASD canmore readily be identified. For example, a
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prominent subgroup of individuals with ASD suffers from
gastrointestinal (GI) dysfunction that stems from yet un-
known causes.
The prevalence of GI symptoms in ASD is substantial,
with common syptoms including diarrhea, constipation,
vomiting/reflux, abdominal pain/discomfort, gaseousness,
and unusually foul-smelling stools [6–8]. Individuals with
ASD who have GI symptoms, compared to those without GI
symptoms, often display significantly highermeasures of irri-
tability, anxiety, and social withdrawal [8]. While these stud-
ies illustrate that GI symptoms are present, the pathophys-
iology of these symptoms is not well understood. Despite
the current lack of evidence surrounding a known GI pathol-
ogy in ASD, almost one-fifth of the physicians encourage
the use of probiotics for children with ASD, according to a
recent survey in the United States [9]. In addition, almost 60
percent of the physicians accept the use of probiotics when
the family is already utilizing them. Thus, the purpose of this
paper is to put forth whether there is a case for clinical testing
of probiotic preparations in selected groups of children with
ASD. Rationale will be presented for the relevance of probi-
otic use not only in groups with GI symptoms but also in
light of other immunologic and intestinal abnormalities
identified in the ASD population.
Probiotics are living nonpathogenic microorganisms,
which beneficially affect the host’s health, when administered
in adequate amounts as food ingredient or supplement.
Probiotic products consist mainly of lactic acid-producing
bacteria, such as lactobacilli, lactococci, and bifidobacte-
ria, or yeasts such as Saccharomyces boulardii. The well-
established health effects of probiotics vary with the species
and particular strain(s) of bacteria chosen, based on genetic
differences and the nature of bacteria-host interactions [10].
Probiotics have been used safely in the fermentations of
food products for decades. Therefore, the United States
Food and Drug Administration has designated probiotics
as Generally Recognized as Safe (GRAS), and the European
authorities provide a list of bacterial species with a Qualified
Presumption of Safety (QPS).
Research on probiotics has shown efficacy of probiotic
bacteria in a wide variety of health problems. Gastroin-
testinal difficulties such as antibiotic-associated and acute
infectious diarrhea, inflammatory bowel disease (IBD), and
irritable bowel syndrome (IBS) have been shown to be
responsive to probiotics. In addition, probiotics have also
shown activity in influencing the host’s immune system [11,
12]. With the growing research on probiotics and the integral
part they play in the health of not just the GI tract but the
body as a whole, their inclusion as an integrative treatment
may be of use for children with ASD.
2. The GI Tract in ASD
A notable proportion of children with ASD suffer from
gastrointestinal (GI) symptoms stemming from unknown
causes. The precise prevalence of GI symptoms in children
with autism is not clear, with estimates ranging from between
9 to 70% [13]. The discrepancy of figures may reflect the
studies reporting these estimates and range from lower
estimates in some population studies to higher estimates
seen in specialized GI clinics. Moreover, the assessment of GI
symptoms and what constitutes GI symptoms accounts for
much variation in these estimates. The fact that GI symptoms
are a significant problem in autism is not in dispute but is
often understated. Since GI symptoms in ASDmay be impor-
tant contributors to behavioral difficulties [13], carefully
designed studies that investigate the full range of symptoms
described for this ASD cohort are required to establish
prevalence values with greater confidence. In agreement with
the idea that the severities of GI symptoms and autistic
symptoms could possibly be linked, Nikolov et al. reported
that children with ASD andGI symptoms, compared to those
without GI symptoms, display significantly higher measures
of irritability, anxiety, and social withdrawal [8]. More
recently, Adams et al. studied 58 children with ASD, mea-
suring both GI symptoms and the severity of autism [14].
Their data showed a strong positive association of autism
severity with GI dysfunction. This association was evident
within each of the subcategories of their autism assessment,
including speech, social, sensory/cognitive, and physical/
behavioural. This important new finding, while not defin-
ing a cause-effect relationship, nevertheless emphasizes the
importance of developing new approaches to relieve GI
symptoms in children with autism.
The GI symptoms associated with ASD are remarkably
similar to those of irritable bowel syndrome (IBS) which
affects 10–20% of the US population. IBS is characterized
by abdominal pain/discomfort which sometimes improves
upon defecation and is associated with changing stool
frequency and/or changing stool consistency [15]. In a given
individual, constipation or diarrhea (or neither) may pre-
dominate. Other symptoms which can accompany IBS (as
well as ASD) include bloating, excess gas, gastric reflux, and
food sensitivities. A careful evaluation of the patient as set
forth in the ROME III criteria for functional bowel disorders
[15] provides the diagnosis of IBS; this approach derives
from the fact that, like ASD, there is no known biological
signature or biomarker for IBS. In another parallel to
ASD, IBS patients commonly have extraintestinal comorbid
conditions, some of which suggest a CNS component. These
include sleep difficulties, anxiety, depression, headache, and
fatigue [16, 17]. Due to the similarity of GI symptoms
between ASD and IBS, an established IBS symptom scoring
system has been employed in the assessment of GI symptoms
in ASD [18].
Based on possible similarities between IBS and GI
symptomatology in ASD, it is pertinent to note the recent
successes in the treatment of IBS with probiotics. Specifically,
a recent meta-analysis [19] of clinical trials highlighted two
well-designed studies reporting that Bifidobacterium infantis
can significantly reduce GI symptoms in IBS. In the first
study, 77 subjects with IBS were evaluated over a 4 week
period for GI symptoms and stool patterns, then randomized
to one of three blinded treatments: Lactobacillus salivarius,
Bifidobacterium infantis 35624, or placebo [20]. Symptoms
including distention/bloating, difficulty with bowel move-
ments, and abdominal discomfort/pain dropped signifi-
cantly in the B. infantis group, compared to placebo, during
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the subsequent 8 week intervention period. These changes
took place quickly, being evident by the end of the first
week of treatment and essentially maximal by two weeks.
In a larger multicenter follow-up study focusing solely on
B. infantis 35624, 362 subjects recruited in a primary care
setting underwent a two-week baseline observation period
then randomization to one of three encapsulated doses of B.
infantis or placebo for a six-week intervention period [21].
Confirming and extending results of the first study, treatment
with B. infantis (108 cfu/day) was associated with marked
improvements such as lessening of (1) bloating/distention,
(2) abdominal pain/discomfort, (3) passage of gas, (4) strain-
ing with defecation, and (5) sense of incomplete evacuation.
Other improvements included scores for (1) bowel habit
satisfaction and (2) global self-assessment of IBS relief. The
improvements in this study were observed after approxi-
mately four weeks, in contrast to two weeks in the first study,
with the slower response attributed to the encapsulated
formulation which may be a less-efficient delivery system.
In conclusion, clear parallels between GI symptoms in ASD
and IBS, along with successes in treating IBS symptoms with
probiotics, make it clear that clinical trials with probiotics in
children with ASD who have GI symptoms are warranted.
3. Microbiota Abnormalities
Some studies suggest that children with ASD have distur-
bances of their intestinal microbiota compared to typically
developing children. In the feces of children with ASD
versus healthy controls, 10-fold higher levels of Clostridium
species were reported, with a greater diversity observed in
the Clostridium species [22]. However, a comparison group
consisting of ASD patients without GI symptoms was not
included, so the relationship between Clostridium species
and GI symptoms could not be clarified. A subsequent study
revealed that there were elevations in three different Clostrid-
ium groups; Clostridium bolteae and Clostridium clusters I
and XI, in individuals with ASD, but unfortunately this study
did not report on the frequency of GI symptoms in the
subjects [23]. More recently, Parracho et al. [24] showed
that the fecal content of the Clostridium histolyticum group,
known toxin producers [25], was elevated in ASD children
compared to healthy unrelated controls but not compared
to healthy siblings. The study included children with ASD
with and without GI symptoms and found that within the
ASD group high levels of Clostridium species were signifi-
cantly associated with GI problems. Moreover, in a recent
pyrosequencing-based study, multiple differences in fecal
microbiota composition were observed among children with
ASD and typically developing controls [26]. These changes
included shifts at the phylum level toward a higher pro-
portion of Bacteroidetes and a lower level of Firmicutes in
autism. At the genus level, several Bifidobacterium species
were lower in autism while Desulfovibrio genus was more
highly represented. In general, the sibling control group was
similar to the ASD group, and it was suggested that this
could result from the transfer of microbial species from
ASD children to unaffected siblings and may represent a risk
factor for ASD rather than the result of ASD pathology. A
recent culture-based assessment of fecal species in autistic
children supports the finding of lower Bifidobacteria levels
[14]. Finally, metabolic phenotypes, some of which can be
influenced by shifts in gut microbial populations, can now be
assessed via measurement of key metabolites in urine. In the
context of autism, Yap et al. have defined intriguing urinary
changes related to amino acid and microbial metabolites
[27]. The relationship, if any, of these altered patterns to the
gut microbiota in autism remains to be established.
The hypothesis that a gut microbial imbalance, such as
the presence of toxin-producing Clostridium species, could
contribute to ASD behavioral symptoms was addressed in a
small study consisting of 11 children with chronic diarrhea
and a late-onset phenotype of ASD [28]. Subjects were
treated for 8 weeks with vancomycin, a strategic drug in the
treatment of chronic Clostridium difficile diarrhea. Scores for
behavior and communication improved significantly during
the treatment period; however, these gains in behavior were
temporarliy and deteriorated in most cases after termination
of the treatment. Unfortunately, GI symptomatology and
fecal flora composition were not reported, and the exper-
imental design suffered from a lack of a control group. In
spite of these shortcomings, this study is the only one of its
kind and suggests that ASD symptoms in a selected group
of children may have a relationship to the composition of
intestinal bacterial species that are sensitive to vancomycin.
Disruption of the balance that exists between different
enteric microbiota populations may predispose an individual
to altered gut motility and secretion, which results in
diarrhea or constipation, symptoms commonly reported in
autistic patients. These changes are, in turn, likely to influ-
ence the balance of enteric microbiota. Probiotics can be use-
ful for maintaining or restoring the balance of the intestinal
microbiota [29]. For example, a probiotic mixture has been
shown to affect both the composition as well as the metabolic
activity of the fecal microbiota in healthy volunteers taking
the antibiotic amoxicillin [30]. In addition, specific strains
of probiotics have been shown to inhibit the growth of
different Clostridium species [31–34]. There is also good in
vivo evidence that probiotics can be useful for the treatment
of Clostridium difficile infections (for a review, see [35]).
By analogy, the testing of probiotics in ASD could reveal
whether they are able to normalize gut microbial popula-
tions, reduce GI symptoms (in those affected), and alleviate
behavioral difficulties.
4. Mucosal Immunity
Several studies have sought to determine whether there
is evidence of intestinal pathology in ASD. Findings of
significant but subtle widespread gastrointestinal pathology
have been noted in children with ASD who have GI
symptoms sufficient to warrant clinical followup [6, 13,
36]. However, the existence of a gastrointestinal pathology
specific to persons with ASD is a controversial topic. His-
tology, immunohistochemistry, and flow cytometry evidence
has consistently shown a subtle, panenteric infiltration of
immune cells such as lymphocytes, monocytes, NK cells, and
eosinophils into the walls of the GI tract in some children
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with ASD, compared with typically developing children
with GI symptoms [37–42]. Furthermore, the infiltrating
lymphocytes exhibit a marked proinflammatory phenotype
with increased CD3+ TNFα+ cells, CD3+ IFNγ+ cells and
reduced regulatory CD3+IL-10+ cells in ASD children with
GI symptoms [38, 39]. The observatons, thus far made,
do not suggest that any pathology is similar to known
inflammatory conditions such as Crohn’s disease, ulcerative
colitis, or celiac disease. Furthermore, intestinal immunolog-
ical abnormalities can also be found in children with typical
development, as well as children with food allergies and
immunodeficiencies [13]. By using two inflammatory mark-
ers in the feces, which are increased in some IBD patients,
there was no evidence found for a link between active (i.e.,
neutrophil related) inflammation in the gut and autism
[43]. Thus, despite evident symptomatology there remains
significant contention as to whether this relates to GI patho-
physiology in ASD, with many proponents and detractors
[44].
Healthy individuals have an intact intestinal barrier,
essential in maintaining health and preventing tissue injury
[45]. Despite the arguments surrounding gut pathology in
ASD, several studies have shown that the integrity of the
intestinal mucosal barrier might be compromised in ASD
[36]. The intestinal barrier quality can be measured by
urinary levels of lactulose and mannitol postoral challenge.
This allows calculation of a lactulose:mannitol ratio, which
is a good marker of small intestinal permeability [45].
Intestinal permeability, measured by the lactulose:mannitol
test, has been shown to be increased in autistic children
compared to healthy controls [46–48]. Furthermore, co-
localization of immunoglobulin G/complement C1q depo-
sition on the basement membrane of epithelium of the GI
tract is observed in ASD children, suggesting the presence of
inflammatory processes and/or an autoimmune component
that may affect the integrity of the mucosal barrier [41, 42].
It has been suggested that this increased permeability could
lead to entering of byproducts of commensal or pathogenic
bacteria as well as food-derived peptides into the blood. This
entry of antigenic material may lead to immune responses
that could affect neuronal signaling, or the material could
directly interact with the peripheral nervous system [47, 48].
However, further testing is required [13], as the studies
thus far have had methodological limitations including small
subject populations. Properly powered prospective studies
with appropriate controls are warranted to address the issues
surrounding epithelial damage and permeability.
Probiotics are capable of stabilizing the mucosal barrier
by increasing mucin expression, reducing bacterial over-
growth, stimulating mucosal immunity (secretory IgA), and
synthesizing antioxidant substances [49]. Although most of
these findings are based on cell culture systems and animal
models, in vivo human work has also revealed enhanced
expression of duodenal epithelial tight junction proteins in
the context of short-term exposure to L. plantarum WCFS1
[50]. This supports the concept that probiotics can have a
role in maintaining or improving gut barrier function in
humans. In addition, specific probiotics have been proven to
be successful in preventing the recurrence of inflammation
in some situations and diseases such as IBD (for reviews
see [51–53]). The controversies surrounding the extent and
the nature of GI pathology in ASD exists, and studies that
address the potential use of probiotics may well have to be
confined to treatment of GI symptoms in ASD as opposed to
clinically defined pathological criteria.
5. Immune Dysfunction
A possible role for immune dysfunction in ASD has been
described for many years, and numerous immune abnormal-
ities have been reported in ASD. However, results are rather
variable and sometimes conflicting, due to the small number
of study subjects, heterogeneous patient populations, and
lack of proper controls [54]. Nevertheless, many findings
point to aberrant immune activation, likely in a subset of
individuals with ASD. These findings include an abnor-
mal ratio of CD4+ to CD8+ T-cells, abnormal or skewed
T-helper-cell (TH1/TH2/TH17) cytokine profiles, elevated
blood monocyte counts, decreased lymphocyte numbers,
self-reactive antibodies to brain and CNS proteins, neuroin-
flammation, imbalance of serum and mucosal immunoglob-
ulin levels and increased nitric oxide mechanism (for
reviews, see [39, 55, 56]). Immuno based therapies have
largely been ignored in autism, but it has been shown that
treatment with anti-inflammatory drugs induce clinical im-
provement in ASD [57].
A large part of the immune system (approximately
80%) is concentrated in and around the intestinal mucosa.
The intestinal microbiota is involved in maturation of the
immune system as demonstrated in studies in germ-freemice
[58]. In turn, the microbiota in the intestines plays an impor-
tant role in the regulation of functions in the immune system
[59]. The immune system can be modulated by probiotic
bacteria, and these effects are highly species and strain
specific [11, 59, 60] with both in vitro cytokine responses
and in vivo systemic effects altered by probiotics [61–67]. The
accumulation of evidence suggests that probiotics play a role
in providing tolerogenic signals. For example, a role for gut
microbiota in autoimmune diseases has been suggested [68]
and is supported by animal models demonstrating positive
effects of probiotics on autoimmune diseases [66, 69, 70].
Although not much evidence has yet been reported on the
effect of probiotics in autoimmunity in humans, a pilot
study indicated positive effects in rheumatoid arthritis [71].
Probiotic bacteria themselves as well as metabolites produced
by a probiotic bacterium have shown to suppress the
activation of MCP-1, a chemokine shown to be dysregulated
in ASD [72–75]. However, it must be noted that the effects
of probiotics on cytokine and chemokine responses are
highly strain specific, and probiotic bacteria differ in their
ability to stimulate anti-inflammatory IL-10 secretion by
peripheral blood mononuclear cells (PBMC) in vitro [76–
78]. Bacterial strains with a good in vitro ratio of anti-
inflammatory cytokines versus proinflammatory cytokines
have been shown to have anti-inflammatory properties in
vivo [76]. In vivo administration of Lactobacillus rhamnosus
GG induced higher IL-10 serum levels in allergic children
[79], but this finding was not confirmed in other studies
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[64, 80]. Thus, while probiotics have good in vitro capac-
ities to induce anti-inflammatory cytokines, their effect on
systemic cytokine profiles remains to be proven and may be
dependent on the microbiota mix in situ.
It is well established that there is bidirectional communi-
cation between the gut, the immune system, and the brain.
For example, psychological stress can induce changes of
the gastrointestinal microbes. On the other hand, intestinal
bacteria can directly communicate with the central nervous
system by the way of the vagal sensory nerve fibers and
the peripheral immune system [81]. Intraventricular admin-
istration of propionic acid, a metabolite produced by gut
bacteria, has been shown in a rat model to change both brain
and behavior in a manner that is consistent with symptoms
associated with ASD; these are not “autistic features” but
may have some validity with ASD [82, 83]. It is possible that
gut-brain interactions may contribute to abnormal neural
development and the subsequent expression of aberrant
behavior. Increased gut permeability may play an important
role in the gut-brain relationship, as partially digested food
and bacterial components can pass into the blood stream
and may interfere directly and indirectly with the central
nervous system. One of these immunoreactive compounds
could be dietary-derived opioid peptides, derived from
gluten and casein. Increased intestinal permeability can also
permit entry of lipopolysaccharides (LPS), a potent proin-
flammatory compound of the cell walls of gram-negative
bacteria. Leakage of lipopolysaccharides from the intestine
might be the trigger for peripheral inflammatory responses
that lead to de novo production of cytokines in the brain.
By improving the epithelial barrier, this may reduce traffic
of bacteria and their byproducts and might be a way to stop
the inflammatory response. One study by Emmanuelle and
colleagues showed increased LPS in the blood of individuals
with ASD, a finding that corresponded to increased circu-
lating IL-6 levels in the periphery and may reflect both an
increased intestinal permeability and activation of immune
responses that result in the production of this proficient
neuromodulating cytokine [84].
Administration of probiotics can have influences on neu-
ronal function, as shown by different studies. For example,
administration of Bifidobacterium infantis in a rat model
of depression showed effects on immune, neuroendocrine,
and central monoaminergic activity [85]. The proinflam-
matory immune response was attenuated, and tryptophan
was elevated by the bifidobacteria treatment. A probiotic
drink containing Lactobacillus casei has also revealed positive
effects on mood and cognition in volunteers [86]. Moreover,
a pilot study in chronic fatigue patients has been performed
with the same probiotic product [87]. Interestingly, almost
all chronic fatigue syndrome patients report neuropsycho-
logical disturbances. The study showed a significant decrease
in anxiety symptoms and suggested follow-up studies to
examine anxiety and depression, including inflammatory
cytokines and other immune mediators, blood tryptophan
levels, and urinary metabolites of neurotransmitters [87].
Mechanisms of action by which probiotics can influence
brain processes are not yet fully elucidated, but likely
involve multiple pathways of the interplay between brain,
gut, and immune system. Maintaining a balance between
host defense and uncontrolled or unresolving inflammation
relies on a mutualistic crosstalk between the immune system
and the microbiome, especially in the maintenance of
intestinal homeostasis, an area of relevance for a subset
of ASDs [88]. Probiotics will become increasingly defined
by strain-specific outcomes as this evolving area of cross-
communication between the respective genes of the host
and the microbiota becomes more clearly defined. Probiotics
may offer a potential therapeutic that could beneficially alter
the gut-brain axis and modify aberrant behaviors related to
altered immune inflammatory outputs.
6. Conclusions and Further Perspectives
Autism spectrum disorders are a diverse group of disorders
caused by a complex interplay between genetic and envi-
ronmental components. There is a range of indications that
alterations in the intestinal microbiota in the gut might con-
tribute to the disorder in a substantial number of individuals.
Probiotics can be useful to restore the microbial balance
in the intestine, to relieve gastrointestinal problems and to
attenuate immunological abnormalities. Whether the use of
probiotics by children with autism can lead to improvements
in behaviors needs to be established in well-controlled
trials with sufficient group sizes. Important for these trials
is the choice of the bacterial strains, as effects of probiotic
bacteria can be highly strain specific.
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